At-home rapid antigen COVID-19 tests were first authorized by the Food and Drug Administration in late 2020 (1-3). In January 2022, the White House launched COVIDTests.gov, which made all U.S. households eligible to receive free-to-the-user at-home test kits distributed by the U.S. Postal Service (2). By May 2022, more than 70 million test kit packages had been shipped to households across the United States (2); however, how these kits were used, and which groups were using them, has not been reported. Data from a national probability survey of U.S. households (COVIDVu), collected during April-May 2022, were used to evaluate awareness about and use of these test kits (4). Most respondent households (93.8%) were aware of the program, and more than one half (59.9%) had ordered kits. Among persons who received testing for COVID-19 during the preceding 6 months, 38.3% used a COVIDTests.gov kit. Among kit users, 95.5% rated the experience as acceptable, and 23.6% reported being unlikely to have tested without the COVIDTests.gov program. Use of COVIDTests.gov kits was similar among racial and ethnic groups (42.1% non-Hispanic Black or African American [Black]; 41.5% Hispanic or Latino [Hispanic]; 34.8% non-Hispanic White [White]; and 53.7% non-Hispanic other races [other races]). Use of other home COVID-19 tests differed by race and ethnicity (11.8% Black, 44.4% Hispanic, 45.8% White, 43.8% other races). Compared with White persons, Black persons were 72% less likely to use other home test kits (adjusted relative risk [aRR] = 0.28; 95% CI = 0.16-0.50). Provision of tests through this well-publicized program likely improved use of COVID-19 home testing and health equity in the United States, particularly among Black persons. National programs to address availability and accessibility of critical health services in a pandemic response have substantial health value.
[1]
J. Brownstein,et al.
Use of At-Home COVID-19 Tests — United States, August 23, 2021–March 12, 2022
,
2022,
MMWR. Morbidity and mortality weekly report.
[2]
K. Chapin,et al.
At-Home Testing for Infectious Diseases: The Laboratory Where You Live.
,
2021,
Clinical chemistry.
[3]
P. Sullivan,et al.
SARS-CoV-2 cumulative incidence, United States, August-December 2020.
,
2021,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4]
D. Kansagara,et al.
Racial and Ethnic Disparities in COVID-19–Related Infections, Hospitalizations, and Deaths
,
2020,
Annals of Internal Medicine.
[5]
P. Sullivan,et al.
Protocol for a national probability survey using home specimen collection methods to assess prevalence and incidence of SARS-CoV-2 infection and antibody response
,
2020,
Annals of Epidemiology.